Company / R&D per Share
Amgen R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$13.54
FY2025
5-year range
$7.12 / $13.54
FY2021-FY2025
Trend
+21.6%
vs FY2024
Sector context
#12 of 208
Health Care
What the data says
Among 208 Health Care companies, Amgen is in the top 6% for r&d per share. R&D per Share has increased for 7 consecutive years, from $5.32 in FY2018 to $13.54 in FY2025.
Based on SEC 10-K filings.
13.54 in FY2025 with a 5-year CAGR of +16.5%. Top quartile in the Health Care sector.
Improved from $8.96 to $13.54 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +21.6%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 208This company $13.54 Sector average $28.82
▼
-53.0% below sector average
Key checks
Key Insights
- Amgen's r&d per share has grown for 7 consecutive years.
- In FY2025, r&d per share increased 21.6% year-over-year.
- Ranks #12 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.54 | +21.6% |
| FY2024 | $11.14 | +24.3% |
| FY2023 | $8.96 | +18.9% |
| FY2022 | $7.54 | +5.9% |
| FY2021 | $7.12 | +12.6% |
| FY2020 | $6.32 | +11.7% |
| FY2019 | $5.66 | +6.4% |
| FY2018 | $5.32 | -3.6% |
| FY2017 | $5.51 | -3.3% |
| FY2016 | $5.70 | +6.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026